



Innovative Cell and Tissue Technology

Press release

April 20, 2011

Gothenburg, Sweden

Conference call – Interim Report

Invitation to attend Vitrolife's conference call regarding presentation of the Interim Report January - March 2011. The presentation will be held in English.

Time: Thursday, April 28, 2011, at 10 a.m. CET.

Registration can be done in advance under the following link:

<https://eventreg1.conferencing.com/webportal3/reg.html?Acc=389437&Conf=178046>

or shortly before time of the conference starts on:

Telephone number: +46 8-505 202 65 (**Please quote: 893523**)

Conference name: Vitrolife

Vitrolife participants:

Magnus Nilsson, CEO

Anne-Lie Sveder, CFO

The press release with Vitrolife's Interim Report will be released at 3 p.m. on April 27.

Before the conference call, slides will be available at the company web page, www.vitrolife.com, under the section Investors/News.

A recorded version of the presentation will be available for seven days on number +46 8-505 203 33 (Sweden, Stockholm) or 020 7031 4064 (UK, London), access code 893523.

Gothenburg, April 20, 2011

Magnus Nilsson
CEO

Queries should be addressed to:

Anne-Lie Sveder, CFO, phone +46 31 721 80 13

Vitrolife is a global biotechnology/medical device Group that works with developing, manufacturing and selling advanced products and systems for the preparation, cultivation and storage of human cells, tissue and organs. The company has business activities within three product areas: Fertility, Transplantation and Stem Cell Cultivation. The Fertility product area works with nutrient solutions (media), cryopreservation products and advanced consumable instruments such as needles and pipettes, for the treatment of human infertility. The Transplantation product area works with solutions and systems to evaluate and maintain organs outside the body in order to select usable organs and keep them in optimal condition while waiting for transplantation. The Stem Cell Cultivation product area works with media and instruments to enable the use and handling of stem cells for therapeutic purposes.

Vitrolife today has approximately 220 employees and its products are sold in more than 85 markets. The company is headquartered in Gothenburg, Sweden, and there are subsidiaries in USA, Australia, France, Italy, United Kingdom and Japan. Production facilities are located in Sweden and the USA. The Vitrolife share is listed on NASDAQ OMX Stockholm, Small Cap.

Vitrolife AB (publ), Box 9080, SE-400 92 Göteborg, Sweden. Corporate identity number 556354-3452.
Tel: +46 31 721 80 00. Fax: +46 31 721 80 90. E-mail: info@vitrolife.com. Website: www.vitrolife.com.

This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.